Register
FDA finds no new or unexpected safety risks associated with pimavanserin use in Parkinsons disease psychosis |
Journal Updates
eMediNexus Coverage from: 
FDA finds no new or unexpected safety risks associated with pimavanserin use in Parkinsons disease psychosis

0 Read Comments                

 An analysis of all postmarketing reports of deaths and serious adverse events (SAEs) reported with the use of Nuplazid (pimavanserin) by the US FDA has found no new or unexpected safety risks associated with Nuplazid (pimavanserin), which is used to treat the hallucinations and delusions of Parkinson’s disease psychosis. In a statement issued September 20, 2018, the FDA said, “the drug’s benefits outweigh its risks for patients with hallucinations and delusions of Parkinson’s disease psychosis”.

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now